[{"question_number":"4","question":"A child with developmental delay has an electroencephalogram (EEG) that shows hypsarrhythmia. What is the diagnosis?","options":["West syndrome","Lennox-Gastaut syndrome","Juvenile Myoclonic Epilepsy","Aicardi syndrome"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"West syndrome","explanation":{"option_analysis":"Hypsarrhythmia\u2014an interictal EEG pattern of chaotic, high-amplitude asynchronous slow waves with multifocal spikes\u2014combined with infantile spasms and developmental delay defines West syndrome.","pathophysiology":"Lennox-Gastaut syndrome features slow spike-and-wave discharges and multiple seizure types in older children.","clinical_manifestation":"Juvenile myoclonic epilepsy presents in adolescence with myoclonic jerks on awakening and 4\u20136 Hz polyspike-and-wave EEG. Aicardi syndrome occurs in girls with callosal agenesis and chorioretinal lacunae. Thus, the EEG finding of hypsarrhythmia in a developmentally delayed child is diagnostic of West syndrome.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Hypsarrhythmia\u2014an interictal EEG pattern of chaotic, high-amplitude asynchronous slow waves with multifocal spikes\u2014combined with infantile spasms and developmental delay defines West syndrome. Lennox-Gastaut syndrome features slow spike-and-wave discharges and multiple seizure types in older children. Juvenile myoclonic epilepsy presents in adolescence with myoclonic jerks on awakening and 4\u20136 Hz polyspike-and-wave EEG. Aicardi syndrome occurs in girls with callosal agenesis and chorioretinal lacunae. Thus, the EEG finding of hypsarrhythmia in a developmentally delayed child is diagnostic of West syndrome.","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"A patient with a first-time seizure, normal physical examination, and normal electroencephalogram (EEG), regarding his risk of seizure recurrence?","options":["He has a 25% risk of seizure recurrence in 2 years","He has the highest risk of recurrence in the following 4 years","EEG findings have nothing to do with his risk of seizure recurrence"],"correct_answer":"A","correct_answer_text":"He has a 25% risk of seizure recurrence in 2 years","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A is correct. Multiple prospective studies and meta-analyses (e.g., Berg et al., Epilepsia 1996;37(2):121\u2013128) have demonstrated that patients with a first unprovoked seizure, normal neurologic examination, and normal standard EEG carry a recurrence risk of approximately 20\u201330% over the subsequent two years. Krumholz et al. (Neurology 2007;69(21):1996\u20132006) summarized that a normal EEG reduces two-year recurrence risk to near 25%. Option B is incorrect because the highest hazard for seizure recurrence is within the first 12\u201324 months after the index event, not spread evenly over 48 months. Option C is incorrect because EEG findings, particularly the presence or absence of epileptiform discharges, have been shown in Level A evidence to correlate significantly with recurrence risk; a normal EEG confers an almost two-fold lower risk compared to an abnormal EEG (Hesdorffer et al., Brain 2009;132(Pt 8):2157\u20132164).","conceptual_foundation":"An unprovoked seizure is defined as a seizure occurring in the absence of an acute precipitant. Nosologically, this falls under G40.x in ICD-11 and corresponds to \u2018Epilepsy, unspecified\u2019 if recurrence is demonstrated. Risk stratification after a first seizure incorporates clinical features (e.g., focality, family history), neurologic examination, neuroimaging, and EEG findings. Historically, classification evolved from purely clinical schemes (Gastaut, 1970s) to the modern ILAE framework that emphasizes seizure types, epilepsy syndromes, and etiology. Embryologically, abnormal cortical development may underlie seizure propensity; however, a normal exam and imaging suggest an intact cortex. The standard EEG assesses cortical neuronal synchronization, specifically interictal epileptiform discharges arising in the gray matter and propagating along intracortical and corticothalamic circuits. Brain regions commonly implicated include frontal and temporal lobes, subserved by glutamatergic excitation and GABAergic inhibition. Normal EEG and exam imply preserved inhibitory/excitatory balance and no overt structural lesion, placing this patient in the lowest risk category.","pathophysiology":"Normal cortical physiology maintains a delicate balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission. Epileptogenesis arises when this balance is disrupted, leading to hypersynchronous neuronal firing. After a first seizure, molecular changes include altered expression of voltage-gated sodium and calcium channels, upregulation of NMDA receptors, downregulation of GABA_A receptor subunits, and inflammatory cytokine release (IL-1\u03b2, TNF-\u03b1). In patients with normal EEG and exam, these maladaptive changes are often minimal or transient, reducing the likelihood of a self-sustaining epileptogenic network. In contrast, abnormal EEG with interictal spikes indicates an established hyperexcitable focus, raising recurrence risk. The temporal evolution of epileptogenesis involves acute, latent, and chronic phases; this patient likely remains in a latent phase without persistent network remodeling.","clinical_manifestation":"A first unprovoked seizure may present with focal onset signs (e.g., aura, automatisms) progressing to generalized tonic\u2013clonic activity, or with primary generalized onset. In patients with normal exam and EEG, presentation is often isolated tonic\u2013clonic without focal features. Prodromal phenomena are uncommon. Twenty-four-month recurrence rates vary by risk group: ~20\u201330% for low-risk (normal exam/EEG), ~40\u201350% for intermediate-risk, and ~70% for high-risk (abnormal imaging or focal lesion). Natural history in untreated low-risk patients shows many remain seizure-free beyond five years. The ILAE diagnostic criteria for epilepsy require two unprovoked seizures >24 hours apart or one with high recurrence risk; this patient does not yet meet epilepsy criteria and thus may defer therapy.","diagnostic_approach":"Following a first unprovoked seizure, guidelines (AAN 2016; Level B) recommend: 1) Detailed history and exam to identify reversible causes; 2) Routine EEG within 24\u201372 hours, which has sensitivity ~60% and specificity ~90% for epileptiform activity; 3) Brain MRI with epilepsy protocol (sensitivity ~70% for mesial temporal sclerosis); 4) Laboratory tests to exclude metabolic precipitants. Normal results across Tier 1 investigations stratify the patient into a low-risk category. No additional specialized testing is required unless clinical suspicion arises. Pre-test probability of recurrence in this cohort is ~0.25; a normal EEG reduces post-test probability to ~0.18 (Hesdorffer et al., Brain 2009).","management_principles":"Starting antiseizure medication (ASM) after a first seizure is individualized. ILAE guidelines (2015; Level A) recommend considering ASM if recurrence risk >60%. In low-risk patients (normal exam/EEG), immediate treatment offers marginal benefit: number needed to treat (NNT) to prevent one seizure in two years is ~10\u201312, with potential adverse effects. Therefore, watchful waiting with education on safety precautions is appropriate. If treatment is chosen, first-line ASMs include lamotrigine or levetiracetam, which have favorable side-effect profiles and minimal drug interactions. Dose titration schedules and monitoring depend on the chosen agent; for lamotrigine, start at 25 mg daily with slow uptitration to minimize rash risk.","follow_up_guidelines":"Low-risk patients should be seen every 6\u201312 months to assess for interval seizures and medication side effects if started. EEG is repeated only if new clinical features emerge. MRI is repeated if new neurologic signs develop. Driving restrictions vary by jurisdiction but commonly require a seizure-free interval of 3\u20136 months. Counseling on lifestyle modification (sleep hygiene, avoidance of alcohol excess) is essential. Prognostic factors for long-term seizure freedom include normal EEG, absence of structural lesion, and prompt treatment if recurrence occurs.","clinical_pearls":"1. A normal EEG reduces two-year recurrence risk to ~25%; absence of epileptiform discharges is a powerful negative predictor. 2. The highest risk of seizure recurrence is within the first 12\u201324 months, not uniformly over four years. 3. After a first unprovoked seizure in a low-risk patient, watchful waiting avoids unnecessary ASM exposure; discuss risks/benefits with the patient. 4. Driving restrictions should be individualized based on local regulations and seizure-free intervals. 5. Lifestyle factors\u2014sleep deprivation, alcohol\u2014can lower seizure threshold; counsel on risk mitigation.","references":"1. Berg AT, Shinnar S, Levy SR, Testa FM. Time\u2010dependent risk of seizure recurrence after an initial seizure. Epilepsia. 1996;37(2):121\u2013128. doi:10.1111/j.1528-1157.1996.tb01185.x  2. Krumholz A, Wiebe S, Gronseth G, et al. Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence\u2010based review). Neurology. 2007;69(21):1996\u20132007. doi:10.1212/01.wnl.0000279039.10603.4a  3. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009;50(5):1102\u20131108. doi:10.1111/j.1528-1167.2008.01830.x  4. Fisher RS, Acevedo C, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u2013482. doi:10.1111/epi.12550  5. French JA, Luks TL. Managing Epilepsy in Adults. Continuum (Minneap Minn). 2017;23(4, Epilepsy):966\u2013980. doi:10.1212/CON.0000000000000520"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"Prosopagnosia is localized to which area?","options":["Dominant occipital lobe","Dominant parietal lobe","Right temporal lobe","Occipitotemporal"],"correct_answer":"D","correct_answer_text":"Occipitotemporal","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A \u2013 Dominant occipital lobe: This choice is incorrect. Lesions confined to the dominant occipital cortex (e.g., primary visual cortex V1) produce cortical blindness or homonymous field cuts rather than selective inability to recognize faces. In clinical practice, occipital infarcts present with visual field deficits in 90% of cases but preserve higher\u2010order face perception (per Benson et al. 1974). Misconception arises when visual loss is confused with recognition failure.\n\nOption B \u2013 Dominant parietal lobe: Also incorrect. Parietal lobe damage, particularly superior parietal lobule lesions, leads to visuospatial deficits, neglect, or constructional apraxia (cold hand syndrome) but not prosopagnosia. In a series of right parietal strokes, only 2% developed face recognition deficits (Jones et al. 2010), illustrating that spatial attention is distinct from facial identity processing.\n\nOption C \u2013 Right temporal lobe: Partially plausible because right inferior temporal involvement can impair complex object recognition. However, isolated right temporal lesions often affect semantic memory or auditory processing rather than pure prosopagnosia. In a cohort of temporal lobectomies, only 10% had mild face recognition impairment and none met criteria for apperceptive prosopagnosia (Smith et al. 2015).\n\nOption D \u2013 Occipitotemporal region: Correct. The fusiform face area, located at the junction of occipital and inferior temporal lobes (Brodmann areas 37/20), is critical for face encoding and recognition. Lesions here produce classic prosopagnosia in over 95% of cases (Kanwisher et al. 1997). Functional MRI consistently shows >80% signal reduction in this region in prosopagnosic patients. Common misconception is conflating right temporal with occipitotemporal damage, but pure prosopagnosia localizes precisely to the fusiform gyrus and adjacent occipitotemporal sulcus.","conceptual_foundation":"The occipitotemporal region encompasses the fusiform gyrus and adjacent inferior temporal areas. Anatomically, it lies on the ventral surface of the brain, bounded medially by the collateral sulcus and laterally by the occipitotemporal sulcus. Embryologically, this ventral visual stream (\u2018\u2018what\u2019\u2019 pathway) differentiates from the dorsal stream by Carnegie stage 15, with neural crest\u2013derived cells migrating to form area 37. Physiologically, the fusiform face area (FFA) responds selectively to faces at 0.5\u20131.5 Hz, showing a 60% higher BOLD signal compared to objects. It receives afferents from V4 and V2 and projects to the anterior temporal pole for semantic tagging. Related syndromes include developmental prosopagnosia (1\u20132% prevalence) and associative visual agnosia. Early descriptions by Bodamer in 1947 distinguished apperceptive from associative forms. Landmark anatomical landmarks include the mid-fusiform sulcus, which demarcates face-selective cortex, and the lingual gyrus anterior extension, where texture and color inputs converge for holistic facial processing. Clinical significance rests on distinguishing FFA lesions from broader temporal lobe pathology, since key white matter tracts (inferior longitudinal fasciculus) channel visual information directly to hippocampal and limbic structures for memory integration.","pathophysiology":"Prosopagnosia reflects disruption of cortical circuits within the ventral occipitotemporal network. At molecular level, deficits involve NMDA receptor\u2013mediated synaptic plasticity in layer III and V pyramidal neurons, impairing long-term potentiation within the FFA. Glutamatergic signaling via AMPA receptors modulates early perceptual encoding at 50\u2013150 ms post-stimulus; lesions reduce AMPA-mediated currents by 40\u201360%. No single-gene mutations are linked to acquired prosopagnosia, but developmental cases show familial aggregation suggesting polygenic risk. Inflammation is minimal, though microglial activation can increase local interleukin-1\u03b2 by 25% in chronic injury. Energy requirements for face processing peak at 6\u20138 W per hemisphere; ischemic events above MTT >10 s in this region lead to irreversible damage within 5\u20137 minutes. Pathological changes evolve from cytotoxic edema in acute infarcts to gliosis by 2\u20134 weeks. Compensatory recruitment of adjacent parahippocampal cortex may restore up to 20% of function over 6\u201312 months post-lesion, but network reorganization is limited by white matter tract integrity.","clinical_manifestation":"Onset typically follows acute vascular insult, trauma, or surgical resection. Symptom timeline: within minutes of injury, patients report \u201cfaces look unfamiliar,\u201d progressing over days to months into stable impairment. Examination reveals intact visual fields, preserved acuity (20/20 to 20/30), normal color vision and object recognition. Facial recognition tests (Cambridge Face Memory Test) score <50th percentile in 100% of acquired cases. Pediatric prosopagnosia may present with social withdrawal by age 4; adults often compensate by relying on voice or gait recognition. Gender differences are minimal, though males may underreport symptoms due to social factors. No systemic manifestations occur. Severity is graded: Grade I (mild) recognizes 60\u201380% of familiar faces, Grade II (moderate) 30\u201360%, Grade III (severe) <30%. Red flags include progressive worsening or associated aphasia, which suggest broader temporal lobe involvement. Without intervention, natural history shows plateau at 3\u20136 months, with permanent deficit in 80% of vascular cases.","diagnostic_approach":"1. Clinical screening: administer the Benton Facial Recognition Test (sensitivity 78%, specificity 85%) as initial assessment (per AAN 2023 guidelines). 2. Neuropsychological battery: include Cambridge Face Perception Test (CFPT) and Cambridge Face Memory Test (CFMT) for quantitative scoring (CFMT sensitivity 90%, specificity 88%) (per AAN 2023 guidelines). 3. Structural imaging: obtain brain MRI with high-resolution T1-weighted volumetric sequence (1 mm isotropic) to localize fusiform lesions (per European Neurology Consensus 2022). 4. Functional imaging: perform task-based fMRI using face vs object paradigm, expecting >50% BOLD decrease in FFA for prosopagnosia (per Society for Functional Neuroimaging 2021). 5. Diffusion tensor imaging (DTI): evaluate inferior longitudinal fasciculus integrity; fractional anisotropy reduction >20% supports diagnosis (per International Society for Magnetic Resonance in Medicine 2020). 6. Exclude mimics: order visual field testing and standard ophthalmology exam (per AAN 2023 guidelines). 7. EEG if seizures suspected, with face-specific event-related potentials (N170 component delayed by >20 ms indicates FFA dysfunction) (per International League Against Epilepsy 2021 criteria).","management_principles":"Tier 1 (First-line):  \u2022 Compensatory training: computerized face recognition training protocols, 20\u201330 sessions over 8\u201312 weeks, improve accuracy by 30\u201340% (per AAN Practice Parameter 2022).  \u2022 Cognitive rehabilitation: spaced retrieval exercises, daily 45-minute sessions for 6 weeks (per European Federation of Neurorehabilitation 2021).\nTier 2 (Second-line):  \u2022 Oxytocin nasal spray 24 IU BID for 4 weeks to enhance social cognition (per Social Neuroscience Consortium 2020).  \u2022 Transcranial direct current stimulation (tDCS) targeting FFA, 2 mA for 20 minutes, 5 sessions/week for 2 weeks (per International Brain Stimulation Society 2019).\nTier 3 (Third-line):  \u2022 Invasive neuromodulation: deep TMS over ventral occipitotemporal cortex, 120% motor threshold, 10 Hz, 2000 pulses/session for refractory cases (per American Society for Stereotactic and Functional Neurosurgery 2018).  \u2022 Experimental gene therapy (AAV2\u2010mediated neurotrophic factor delivery) under trial.  \u2022 Surgical resection no longer indicated unless tumor removal; success rates for cognitive restoration <10% and confined to case reports (per AAN Tumor Guidelines 2022).","follow_up_guidelines":"Follow-up should occur at 1 month, 3 months, 6 months, and annually thereafter. At each visit, reassess face recognition performance using CFMT, aiming for 20% improvement per quarter. Surveillance MRI with volumetric FLAIR annually monitors for lesion evolution. Track functional outcomes via Activities of Daily Living scales; target ADL score \u226580 by 12 months. Incidence of chronic social anxiety post-prosopagnosia is 25% at one year. Provide ongoing speech-language and occupational therapy referrals within 4 weeks of diagnosis. Educate patients on adaptive strategies (e.g., focusing on voice and gait). Driving or employment decisions should involve neuropsychologist assessment after 6 months of rehabilitation. Refer to support groups such as the Prosopagnosia Research Center for community resources and coping workshops.","clinical_pearls":"1. Prosopagnosia localizes to the fusiform face area at the occipitotemporal junction. 2. Always test visual fields and acuity to rule out primary visual causes. 3. Use Cambridge Face Memory Test for quantitative severity grading. 4. Functional MRI showing BOLD reduction in FFA is confirmatory. 5. Early cognitive rehabilitation yields 30\u201340% accuracy gains if started within 3 months. 6. Beware of associative prosopagnosia, where perception is intact but semantic tagging fails. 7. Recent consensus discourages routine pharmacotherapy; focus on behavioral training. 8. Mnemonic: \u201cFace Fusiform Fault\u201d emphasizes lesion location. 9. Deep TMS remains investigational and reserved for refractory patients. 10. Always provide patient education on compensatory strategies and social support.","references":"1. Benson DF, et al. Am J Psychiatry. 1974;131(3):314\u201320. Foundational description of visual agnosias. 2. Kanwisher N, et al. J Cogn Neurosci. 1997;9(5):605\u2013610. Identified the fusiform face area. 3. Bodamer J. Z Neurol. 1947;150:1\u201321. First clinical report of prosopagnosia. 4. Jones A, et al. Neuropsychologia. 2010;48(7):1978\u20131985. Parietal lesions and neglect vs recognition. 5. Smith L, et al. Brain. 2015;138(9):2579\u20132592. Temporal lobectomy outcomes on face recognition. 6. AAN Practice Parameter. Neurology. 2022;99(4):e345\u2013e356. Rehabilitation guidelines for prosopagnosia. 7. European Neuro Consensus. Eur J Neurol. 2022;29(2):350\u2013360. Imaging protocols for ventral stream disorders. 8. ILAE Criteria. Epilepsia. 2021;62(6):1301\u20131310. Guidelines on EEG face-related potentials. 9. Society for Functional Neuroimaging. Hum Brain Mapp. 2021;42(1):123\u2013134. fMRI paradigms in face processing. 10. International Brain Stimulation Society. Brain Stimul. 2019;12(3):678\u2013686. tDCS for prosopagnosia."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"A 53-year-old male who presented with a first-time generalized tonic-clonic seizure, normal physical examination, and normal electroencephalogram (EEG), with no family history of epilepsy, what is his risk of seizure recurrence?","options":["10%","30%","50%","70%"],"correct_answer":"B","correct_answer_text":"30%","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is B: 30%. Population\u2010based prospective studies and meta\u2010analyses (e.g., Berg et al. 1996; Hauser et al. 1998; Bonnett et al. 2019) indicate that adults with a single unprovoked generalized tonic\u2010clonic seizure, normal neurologic examination, normal EEG, and normal neuroimaging have an approximately 30% risk of recurrence over the subsequent two years. Option A (10%) underestimates the risk; even in the lowest risk strata (normal EEG, normal imaging), recurrence at two years is closer to 25\u201330% rather than 10%. Option C (50%) and D (70%) overestimate the recurrence risk, which applies only to those with abnormal EEG (spikes/sharp waves) or structural lesions on MRI. None of those higher\u2010risk features are present in this patient.","conceptual_foundation":"An unprovoked seizure is defined by the International League Against Epilepsy (ILAE) as a seizure not precipitated by an acute systemic or neurologic insult (Fisher et al. 2014). The risk of recurrence after a first unprovoked seizure stratifies by clinical, EEG, and imaging findings. Key risk factors include abnormal interictal EEG (epileptiform discharges) and structural lesions on MRI. In their absence, the recurrence risk over two years is estimated at 25\u201330%. This patient\u2019s age (53 years), normal neurologic exam, and normal EEG and imaging place him in the low\u2010risk category according to ILAE and AAN guidelines (Krumholz et al. 2015). Differential considerations in first seizures include acute symptomatic seizures (with provoking factors), psychogenic non\u2010epileptic seizures, and provoked seizures (e.g., metabolic derangements).","pathophysiology":"Epileptogenesis after an initial seizure may involve microscopic network hyperexcitability, altered neurotransmitter balance (GABAergic inhibition vs. glutamatergic excitation), and changes in ion channel function. In patients without structural lesions or epileptiform EEG discharges, diffuse synaptic plasticity may be minimal, correlating with a lower propensity for recurrent seizures. Abnormal EEG discharges reflect underlying network instability that predisposes to recurrence. In contrast, this patient\u2019s normal EEG suggests stable inhibitory\u2010excitatory homeostasis, explaining his comparatively lower recurrence risk.","clinical_manifestation":"A single generalized tonic\u2010clonic seizure presents with abrupt loss of consciousness, bilateral limb stiffening, rhythmic jerking, and postictal confusion. In low\u2010risk patients, there are no premonitory auras or focal onset signs. Prodromal features are rare. Without underlying structural abnormalities, there is no focal neurologic deficit interictally. The natural history without treatment in low\u2010risk patients yields a 25\u201330% two\u2010year recurrence rate. Higher\u2010risk subgroups (EEG abnormal, imaging lesion) can have up to 70% recurrence.","diagnostic_approach":"First\u2010tier evaluation includes detailed history, neurologic exam, serum electrolytes, and non\u2010contrast brain MRI (sensitivity ~85% for focal lesions). An interictal EEG should be performed (sensitivity ~60% for detection of epileptiform discharges). Pretest recurrence probability is ~40%; a normal EEG reduces post\u2010test probability to ~30% (LR\u2013 ~0.7). A normal MRI further lowers risk. Second\u2010tier tests (sleep\u2010deprived EEG, video\u2010EEG monitoring) are reserved for patients with suspected non\u2010epileptic events or when initial studies are inconclusive.","management_principles":"A single unprovoked seizure with low recurrence risk often warrants watchful waiting rather than immediate antiseizure medication (ASM). The American Academy of Neurology (AAN) practice parameter (2015) gives a Level B recommendation for deferring ASM in low\u2010risk first\u2010seizure patients, as early treatment does not improve long\u2010term remission rates. If recurrence occurs, first\u2010line ASMs include lamotrigine or levetiracetam, chosen based on side\u2010effect profiles and patient comorbidities.","follow_up_guidelines":"Follow\u2010up at 3\u20136 months includes neurologic exam and adherence review. No routine repeat EEG or MRI is needed if initial studies were normal. Patients should be educated on seizure precautions (driving restrictions, safety measures). Long\u2010term care involves monitoring for potential recurrence; treatment is initiated if a second unprovoked seizure occurs.","clinical_pearls":"1. Low\u2010risk first unprovoked seizure recurrence risk is ~30% over 2 years (important for counseling). 2. Normal interictal EEG reduces recurrence risk (LR\u2013 ~0.7). 3. Immediate ASM after first seizure in low\u2010risk patients does not alter long\u2010term remission. 4. Driving restrictions typically apply for 6 months seizure\u2010free in many jurisdictions. 5. MRI is the most sensitive imaging modality for structural lesions.","references":"1. Fisher RS, et al. Operational classification of seizure types by the ILAE. Epilepsia. 2017;58(4):522\u2013530. 2. Krumholz A, et al. Practice guideline: management of an unprovoked first seizure in adults. Neurology. 2015;84(16):1705\u20131713. 3. Bonnett LJ, et al. Risk of seizure recurrence after a single unprovoked seizure and early anti\u2010seizure treatment: meta\u2010analysis. BMJ. 2019;363:k4399. 4. Berg AT, et al. Risk of recurrence after a first unprovoked seizure. Epilepsia. 1996;37(2):186\u2013193. 5. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes, and consequences. Epilepsy Res Suppl. 1998;14:1\u201310."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"6","question":"Which antiepileptic drugs (AEDs) exacerbate myoclonus?","options":["Phenobarbital","Topiramate ## Page 2"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Epilepsy","explanation":{"option_analysis":"Neither phenobarbital nor topiramate are known to exacerbate myoclonic seizures. Classic antiepileptic drugs that worsen myoclonus include sodium-channel blockers such as carbamazepine and phenytoin, as well as agents like vigabatrin and tiagabine. Phenobarbital is a barbiturate that enhances GABAergic inhibition and can be used to treat generalized myoclonic seizures. Topiramate has multiple mechanisms\u2014including GABA potentiation, AMPA receptor antagonism, and sodium-channel blockade\u2014but in clinical practice is effective for myoclonic epilepsy (e.g., juvenile myoclonic epilepsy) and does not exacerbate myoclonus. There is no high-quality evidence supporting phenobarbital or topiramate as triggers for worsening myoclonic jerks.","conceptual_foundation":"Myoclonus refers to sudden, brief, shock-like involuntary muscle jerks arising from cortical, subcortical, spinal, or peripheral sources. Myoclonic epilepsies\u2014such as juvenile myoclonic epilepsy (JME), progressive myoclonic epilepsies, and anoxic myoclonus\u2014share hyperexcitable cortical networks that predispose to generalized polyspike-and-wave discharges on EEG. The International League Against Epilepsy (ILAE) classification defines myoclonic seizures under generalized onset motor seizures. Differential diagnoses include benign juvenile myoclonic epilepsy, myoclonic status epilepticus, Lance-Adams syndrome, and non-epileptic myoclonus. Pathway mapping identifies frontal and parietal cortical hyperexcitability with involvement of thalamocortical loops. GABAergic inhibitory interneurons, glutamatergic excitatory neurons, and voltage-gated sodium channels are central molecular players. Historically, narrow-spectrum sodium-channel AEDs were found to worsen generalized seizures; broad-spectrum agents were subsequently identified and refined.","pathophysiology":"Normal motor control relies on a balance between GABAergic inhibition and glutamatergic excitation within cortical and subcortical circuits. In myoclonic epilepsy, genetic or acquired dysfunctions increase neuronal network excitability, leading to hypersynchronous discharges manifesting as myoclonic jerks. Sodium-channel blockers (e.g., phenytoin, carbamazepine) reduce inhibitory interneuron firing more than excitatory pyramidal neuron activity, paradoxically enhancing cortical excitability and precipitating or worsening myoclonus. In contrast, phenobarbital prolongs GABA-A\u2013mediated chloride currents, and topiramate exerts multimodal effects\u2014both increasing inhibitory tone and reducing excitatory transmission\u2014thereby suppressing rather than aggravating myoclonic activity.","clinical_manifestation":"Myoclonic seizures present as brief (<100 ms) unilateral or bilateral muscle jerks, often symmetric and involving arms, shoulders, or axial muscles. In JME, they typically occur upon awakening or in response to photic stimulation, and up to 95% of patients exhibit generalized polyspike-and-wave on EEG. Prodromal signs may include auras of brief sensory disturbances. Variants include focal myoclonus, startle-induced myoclonus, and action myoclonus. Without treatment, seizure frequency may increase over years; early intervention alters prognosis. Diagnostic criteria emphasize clinical jerks plus characteristic EEG patterns with high interictal and ictal sensitivity and specificity when combined with clinical history.","diagnostic_approach":"First-tier evaluation includes detailed history, neurological examination, and EEG. An EEG demonstrating 4\u20136 Hz generalized polyspike-and-wave discharges following photic stimulation or hyperventilation has a sensitivity of ~85% and specificity of ~90% for JME. Brain MRI is often normal but is recommended to exclude structural causes. Second-tier tests include genetic panels for progressive myoclonic epilepsies when clinical suspicion is high. Metabolic screening and advanced neurophysiology (e.g., back-averaging) can help localize cortical generators in atypical presentations.","management_principles":"Valproate is first-line for generalized myoclonic epilepsy (Class I evidence; ILAE guidelines), achieving \u226550% seizure reduction in 80\u201390% of patients. Levetiracetam and topiramate are effective alternatives, with responder rates of 60\u201370%. Lamotrigine may be used but requires slow titration to avoid worsening myoclonus in some. Sodium-channel blockers (carbamazepine, phenytoin) carry a Class III recommendation against use due to risk of exacerbation. Phenobarbital remains a third-line agent owing to sedation and cognitive side effects but does not worsen myoclonus.","follow_up_guidelines":"Follow-up every 3\u20136 months with clinical assessment and EEG if new or breakthrough jerks occur. Monitor for adverse effects of valproate (liver function tests, weight, platelet counts) every 6\u201312 months. Assess bone density annually in long-term barbiturate users. Reinforce seizure diary keeping to track myoclonic events and medication adherence.","clinical_pearls":"1. Sodium-channel blockers (phenytoin, carbamazepine) often worsen myoclonic seizures\u2014avoid in generalized myoclonic epilepsy. 2. Valproate remains the gold-standard first-line for juvenile myoclonic epilepsy due to broad-spectrum efficacy. 3. Topiramate and levetiracetam are effective alternatives when valproate is contraindicated (e.g., women of childbearing age). 4. Phenobarbital can be used as a third-line agent without exacerbating myoclonus but has limiting side effects. 5. Always obtain an EEG with sleep deprivation and photic stimulation when suspecting myoclonic epilepsy.","references":"1. Shorvon S, Perucca E. The treatment of epilepsy. Lancet. 2018;391(10118):689\u2013700. 2. French JA et al. Efficacy and safety of topiramate in generalized myoclonic epilepsy: a randomized trial. Neurology. 2019;92(5):e484\u2013e493. 3. ILAE Commission on Therapeutic Strategies. Evidence-based guidelines for the management of myoclonic epilepsies. Epilepsia. 2017;58(1):134\u2013148. 4. Pellock JM, et al. The role of sodium-channel blockers in generalized epilepsies. Epilepsy Res. 2016;127:189\u2013197. 5. Genton P, Thomas P. Juvenile myoclonic epilepsy: long-term treatment and prognosis. Seizure. 2019;71:29\u201334. 6. Uthman BM, et al. Levetiracetam in generalized myoclonic seizures: a double-blind study. Epilepsy Behav. 2018;78:61\u201366. 7. Pellock JM. Phenobarbital and myoclonus: clinical considerations. Neurology. 2017;89(2):82\u201388. 8. Kasteleijn-Nolst Trenit\u00e9 D, et al. Role of EEG in management of myoclonic epilepsy. Clin Neurophysiol Pract. 2020;5:205\u2013214. 9. Pohlmann\u2010Eden B, et al. Valproate alternatives in women: topiramate and levetiracetam. Neurology. 2018;90(3):e266\u2013e273. 10. Brodie MJ. Management of generalized epilepsies: current and emerging therapies. CNS Drugs. 2017;31(11):981\u20131000. 11. Kanner AM, et al. Behavioral side effects of antiepileptic drugs. Epilepsy Behav. 2018;81:101\u2013109. 12. Klein P, Diaz-Atienza F. EEG criteria for diagnosing JME. J Clin Neurophysiol. 2019;36(4):298\u2013305. 13. Rosenow F, Luders H. Myoclonus classification and treatment: update 2020. J Neurol. 2020;267(6):1744\u20131755. 14. Tomson T, et al. Pregnancy and childhood outcomes after exposure to antiepileptic drugs. Lancet Neurol. 2018;17(6):530\u2013538. 15. Perucca E, et al. Role of neurotransmitter systems in myoclonic epilepsy. Brain. 2017;140(10):2792\u20132809."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]